See also: Generic Apidra Solostar
Apidra is a brand name of insulin glulisine, approved by the FDA in the following formulation(s):
APIDRA (insulin glulisine recombinant - injectable; iv (infusion)-sc)
Manufacturer: SANOFI AVENTIS US
Approval date: April 16, 2004
Strength(s): 1000 UNITS/10ML (100 UNITS/ML) [RLD]
Manufacturer: SANOFI AVENTIS US
Approval date: December 20, 2005
Strength(s): 300 UNITS/3ML (100 UNITS/ML) [RLD]
Has a generic version of Apidra been approved?
No. There is currently no therapeutically equivalent version of Apidra available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Apidra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Insulin derivatives having a rapid onset of action
Patent 6,221,633
Issued: April 24, 2001
Inventor(s): Ertl; Johann & Habermann; Paul & Geisen; Karl & Seipke; Gerhard
Assignee(s): Aventis Pharma Deutschland GmbH
The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.
Patent expiration dates:
Zinc-free and low-zinc insulin preparations having improved stability
Patent 6,960,561
Issued: November 1, 2005
Inventor(s): Boderke; Peter
Assignee(s): Aventis Pharma Deutschland GmbH
The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
Patent expiration dates:
Zinc-free and low-zinc insulin preparations having improved stability
Patent 7,452,860
Issued: November 18, 2008
Inventor(s): Boderke; Peter
Assignee(s): Sanofi-Aventis Deutschland GmbH
The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
Patent expiration dates:
- March 22, 2022
✓
Drug product
Zinc-free and low-zinc insulin preparations having improved stability
Patent 7,696,162
Issued: April 13, 2010
Inventor(s): Boderke; Peter
Assignee(s): Sanofi-Aventis Deutschland GmbH
The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
Patent expiration dates:
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
See also...
- Apidra Consumer Information (Drugs.com)
- Apidra Cartridges Consumer Information (Wolters Kluwer)
- Apidra Vials Consumer Information (Wolters Kluwer)
- Apidra Consumer Information (Cerner Multum)
- Apidra OptiClik Cartridge Consumer Information (Cerner Multum)
- Apidra Advanced Consumer Information (Micromedex)
- Apidra AHFS DI Monographs (ASHP)
- Insulin Glulisine Cartridges Consumer Information (Wolters Kluwer)
- Insulin Glulisine Pens Consumer Information (Wolters Kluwer)
- Insulin Glulisine Vials Consumer Information (Wolters Kluwer)
- Insulin glulisine Consumer Information (Cerner Multum)
- Insulin glulisine Subcutaneous Advanced Consumer Information (Micromedex)
- Insulin Glulisine AHFS DI Monographs (ASHP)
